Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Myeloid Therapeutics
Genentech, Inc.
Jonsson Comprehensive Cancer Center
Avacta Life Sciences Ltd
Innate Pharma
Incyte Corporation
Pfizer
Tempest Therapeutics
Nurix Therapeutics, Inc.
Pfizer
Exelixis
Jonsson Comprehensive Cancer Center
Xencor, Inc.
University of Virginia
Incyte Corporation
NextPoint Therapeutics, Inc.
Monopar Therapeutics
Monopar Therapeutics
Checkpoint Therapeutics, Inc.
Carisma Therapeutics Inc
Molecular Templates, Inc.
Pfizer
Xencor, Inc.
Pliant Therapeutics, Inc.
University of Florida
Fate Therapeutics
Fate Therapeutics
Xencor, Inc.
Herlev Hospital
Xencor, Inc.
Ludwig Institute for Cancer Research
Incyte Corporation
Eisai Inc.
Incyte Corporation
Celgene
Merrimack Pharmaceuticals
Corcept Therapeutics